Table 1.
Variables | ZDV Group (N=106) | TDF Group (N=106) | P-value | ||
---|---|---|---|---|---|
Frequency | Valid % | Frequency | Valid % | ||
Sex | |||||
Male | 47 | 44.30 | 49 | 46.20 | 0.783 |
Female | 59 | 55.70 | 57 | 53.80 | |
Regular income | |||||
No | 54 | 50.90 | 46 | 43.40 | 0.271 |
Yes | 52 | 49.10 | 60 | 56.60 | |
Participants age | |||||
20–29 | 21 | 19.80 | 12 | 11.30 | 0.549 |
30–39 | 30 | 28.30 | 34 | 32.10 | |
40–49 | 33 | 31.10 | 35 | 33.00 | |
50–59 | 14 | 13.20 | 17 | 16.00 | |
60–69 | 8 | 7.50 | 8 | 7.50 | |
Educational status | |||||
Unable to read/write | 14 | 13.20 | 22 | 20.80 | 0.432 |
Elementary | 41 | 38.70 | 40 | 37.70 | |
High school | 29 | 27.40 | 22 | 20.80 | |
Diploma and above | 22 | 20.80 | 22 | 20.80 | |
Religion | |||||
Orthodox | 94 | 88.70 | 95 | 89.60 | 0.825 |
Muslims | 12 | 11.30 | 11 | 10.40 | |
Residence | |||||
Rural | 10 | 9.40 | 14 | 13.20 | 0.386 |
Urban | 96 | 90.60 | 92 | 86.80 |
Abbreviations: ZDV, zidovudine; TDF, tenofovir.